<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Funct Morphol Kinesiol</journal-id><journal-id journal-id-type="iso-abbrev">J Funct Morphol Kinesiol</journal-id><journal-id journal-id-type="publisher-id">jfmk</journal-id><journal-title-group><journal-title>Journal of Functional Morphology and Kinesiology</journal-title></journal-title-group><issn pub-type="epub">2411-5142</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407432</article-id><article-id pub-id-type="pmc">PMC12101145</article-id>
<article-id pub-id-type="doi">10.3390/jfmk10020148</article-id><article-id pub-id-type="publisher-id">jfmk-10-00148</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Relationship Between Systemic Inflammation and Glycemic Control in Firefighters</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oberther</surname><given-names>Tiffany J.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7021-0383</contrib-id><name><surname>Moore</surname><given-names>Andrew R.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0755-698X</contrib-id><name><surname>Kohler</surname><given-names>Austin A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2676-284X</contrib-id><name><surname>Holland-Winkler</surname><given-names>A. Maleah</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="c1-jfmk-10-00148" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Gorce</surname><given-names>Philippe</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jfmk-10-00148">Department of Kinesiology, Augusta University, Augusta, GA 30909, USA<email>andmoore@augusta.edu</email> (A.R.M.); <email>akohler@augusta.edu</email> (A.A.K.)</aff><author-notes><corresp id="c1-jfmk-10-00148"><label>*</label>Correspondence: <email>awinkler@augusta.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>148</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>21</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Firefighters are at risk for developing metabolic diseases such as type 2 diabetes due to occupational-related stress and poor health behaviors. Firefighters often experience chronic inflammatory responses that may contribute to the development of insulin resistance. This study examined the relationship between systemic inflammation markers and glycemic control markers in firefighters. <bold>Methods</bold>: Blood samples were collected from twenty full-time male firefighters to assess HbA1c, fasting glucose, and insulin to estimate the Homeostatic Model of Assessment of Insulin Resistance (HOMA-IR), C-reactive protein (CRP), and homocysteine. Body composition and cardiovascular metrics were also recorded. Pearson partial correlation analyses were performed to evaluate relationships between homocysteine and CRP and the variables HOMA-IR and HbA1c while controlling for age and body fat percentage (BF%). SPSS version 29 was used for all analyses (&#x003b1; = 0.05). Data transformation was used where appropriate to ensure the normal distribution of each variable. <bold>Results</bold>: A significant positive correlation was found between homocysteine and HbA1c before (<italic toggle="yes">p</italic> = 0.006, <italic toggle="yes">r</italic> = 0.605) and after controlling for age and BF% (<italic toggle="yes">p<sub>partial</sub></italic> = 0.013, <italic toggle="yes">r<sub>partial</sub></italic> = 0.588), indicating that homocysteine levels are associated with impaired glycemic control in firefighters. No other relationships were found to be significant. <bold>Conclusions</bold>: The findings support a potential link between systemic inflammation and poor glycemic control in firefighters. Due to the occupational hazards that contribute to chronic inflammation, targeted interventions such as dietary modifications may help decrease the risk of diabetes and cardiovascular disease in this high-risk population.</p></abstract><kwd-group><kwd>inflammation</kwd><kwd>diabetes</kwd><kwd>insulin resistance</kwd><kwd>HOMA-IR</kwd><kwd>C-reactive protein</kwd><kwd>tactical athletes</kwd><kwd>homocysteine</kwd><kwd>HbA1c</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-jfmk-10-00148"><title>1. Introduction</title><p>About 537 million instances of diabetes have been reported worldwide, with type 2 diabetes accounting for about 90% of these cases [<xref rid="B1-jfmk-10-00148" ref-type="bibr">1</xref>]. The prevalence of type 2 diabetes is still rising worldwide due to the rise in obesity-related sedentary lifestyles and bad eating habits [<xref rid="B2-jfmk-10-00148" ref-type="bibr">2</xref>]. Type 2 diabetes is a complicated, cardiorenal&#x02013;metabolic disease entity that is brought on by consistently high blood glucose levels [<xref rid="B1-jfmk-10-00148" ref-type="bibr">1</xref>]. Multi-organ insulin resistance and a reduction in beta cell insulin secretory function are the causes of this condition [<xref rid="B3-jfmk-10-00148" ref-type="bibr">3</xref>].</p><p>Firefighters frequently operate in physically and psychologically challenging environments while playing a vital role in preserving lives and property. But according to recent research, firefighters are more likely than members of other professional groups to develop type 2 diabetes, even though they lead an active lifestyle [<xref rid="B4-jfmk-10-00148" ref-type="bibr">4</xref>]. Numerous environmental and occupational factors, such as high stress levels, disturbed sleep cycles, and obesogenic behaviors, including irregular eating habits, are blamed for this elevated risk [<xref rid="B5-jfmk-10-00148" ref-type="bibr">5</xref>]. These illnesses increase the risk of insulin resistance and diabetes by causing metabolic abnormalities [<xref rid="B4-jfmk-10-00148" ref-type="bibr">4</xref>]. Furthermore, diabetes might affect a firefighter&#x02019;s physical skills and response time during emergencies, as firefighters must maintain optimal physical performance to carry out their jobs safely [<xref rid="B6-jfmk-10-00148" ref-type="bibr">6</xref>].</p><p>The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and glycated hemoglobin (HbA1c) are two essential biomarkers for diabetes management. Average blood glucose levels during the two or three months prior to testing are reflected in HbA1c, which offers a trustworthy indicator of long-term glycemic control [<xref rid="B7-jfmk-10-00148" ref-type="bibr">7</xref>]. Elevated HbA1c values in firefighters are cause for concern, as they indicate inadequate glucose management, which may impair their physical capabilities during demanding tasks. However, insulin resistance, a crucial element in the development of type 2 diabetes from metabolic disorders, is measured by the HOMA-IR [<xref rid="B8-jfmk-10-00148" ref-type="bibr">8</xref>]. Increased HOMA-IR levels suggest a reduced capacity to use insulin efficiently, putting firemen at risk for consequences from diabetes, including cardiovascular disease [<xref rid="B9-jfmk-10-00148" ref-type="bibr">9</xref>].</p><p>In addition to diabetes, systemic inflammation is another condition to which firefighters are especially vulnerable. Inflammatory reactions that may continue beyond firefighting operations are caused by exposure to heat, smoke, and air pollutants during fire suppression activities [<xref rid="B10-jfmk-10-00148" ref-type="bibr">10</xref>]. Firefighters have been found to have elevated levels of inflammatory markers, including interleukin-6 (IL-6) and C-reactive protein (CRP), which are associated with an increased risk of metabolic and cardiovascular disorders [<xref rid="B10-jfmk-10-00148" ref-type="bibr">10</xref>,<xref rid="B11-jfmk-10-00148" ref-type="bibr">11</xref>,<xref rid="B12-jfmk-10-00148" ref-type="bibr">12</xref>]. Despite their initial protective effects, these inflammatory reactions raise the likelihood of long-term health issues like insulin resistance and type 2 diabetes [<xref rid="B13-jfmk-10-00148" ref-type="bibr">13</xref>].</p><p>Homocysteine and C-reactive protein (CRP) are two significant inflammatory markers that offer information on the degree of systemic inflammation. Increased oxidative stress and endothelial dysfunction, two major causes of cardiovascular disease, have been linked to elevated homocysteine [<xref rid="B14-jfmk-10-00148" ref-type="bibr">14</xref>]. Likewise, CRP, an acute-phase reactant, has been connected to the onset of diabetes and cardiovascular problems and increases in response to inflammatory stimuli [<xref rid="B15-jfmk-10-00148" ref-type="bibr">15</xref>]. Firefighters with elevated CRP have chronic inflammation, which worsens insulin resistance and raises the risk of abrupt cardiac events [<xref rid="B16-jfmk-10-00148" ref-type="bibr">16</xref>,<xref rid="B17-jfmk-10-00148" ref-type="bibr">17</xref>,<xref rid="B18-jfmk-10-00148" ref-type="bibr">18</xref>].</p><p>It is widely acknowledged that inflammation and diabetes are related to one another. It has been demonstrated that persistent low-grade inflammation disrupts insulin signaling and encourages &#x003b2;-cell malfunction, two important pathways in the etiology of type 2 diabetes [<xref rid="B19-jfmk-10-00148" ref-type="bibr">19</xref>]. A feedback loop that prolongs metabolic dysfunction and makes managing diabetes more difficult is created when proinflammatory cytokines like IL-6 and CRP exacerbate insulin resistance [<xref rid="B20-jfmk-10-00148" ref-type="bibr">20</xref>].</p><p>This study aimed to determine the correlation between diabetic and inflammatory markers in firefighters. Prior studies have found that the related medical conditions of inflammation and diabetes pose a significant obstacle for firefighters. Controlling these factors is essential for the safety and effectiveness of firefighting operations and the health of each firefighter. Targeted therapies that address the dual dangers of diabetes and inflammation can improve firefighters&#x02019; health and keep them fit for duty with the ability to respond to emergencies.</p></sec><sec id="sec2-jfmk-10-00148"><title>2. Materials and Methods</title><sec id="sec2dot1-jfmk-10-00148"><title>2.1. Study Design</title><p>A cross-sectional design was used to determine the relationship between diabetic and inflammatory markers in full-time firefighters in the southeastern part of the United States. All participants had their blood drawn during the same week in July 2024 to assess diabetic and inflammatory markers. Body composition and cardiovascular characteristics were measured in a separate laboratory visit within two weeks of the blood draw. This study was approved by the University&#x02019;s Institutional Review Board (IRBNet ID: 2095651), all procedures performed followed institutional guidelines, and all participants signed an informed consent.</p></sec><sec sec-type="subjects" id="sec2dot2-jfmk-10-00148"><title>2.2. Participants</title><p>Twenty full-time male firefighters (39.4 &#x000b1; 12.5 years old) participated in this study. All were employed by the same fire department, which consists of 16 different stations. While both males and females were eligible for inclusion, only males volunteered, as they represent over 98% of the department. Participants were excluded if they were (1) pregnant or (2) using vasoactive medications, including catecholamines, phosphodiesterase inhibitors, calcium sensitizers, or vasopressors.</p></sec><sec id="sec2dot3-jfmk-10-00148"><title>2.3. Protocol</title><p>During the initial meeting, the participants provided a list of their medications to verify eligibility based on the inclusion criteria. They then signed an informed consent form to participate in the study. Preparation instructions were given for the blood draw and the body composition and cardiovascular health assessment visits, which were scheduled to take place within two weeks of each other.</p><sec id="sec2dot3dot1-jfmk-10-00148"><title>2.3.1. Body Composition and Cardiovascular Health Assessment</title><p>The preparatory instructions for body composition and cardiovascular health assessment included fasting with only water and abstaining from nicotine and antioxidant vitamins for 12 h, alcohol for 24 h, and moderate-to-vigorous intensity exercise for 8 h prior to the visit.</p><p>Height was measured with shoes off via a wall stadiometer (Stadi-o-meter; Novel Products, Inc., Rockton, IL, USA). A bioelectrical impedance scale (InBody 580 Body Composition Analyzer, Cerritos, CA, USA) was used to measure weight, BMI, and body fat percentage (BF%).</p><p>Cardiovascular health assessments were taken in the morning with a clinical multifunctional vascular testing system (PWV; Vicorder, 80 Beats Medical GmbH, Kantstrasse, Berlin, Germany) after participants rested in the supine position for 10 min. The cardiovascular health assessments included two vascular tests: pulse wave analysis and pulse wave velocity.</p><p>After resting for 10 min in the supine position, the participants continued to rest for the pulse wave analysis test. A pressure cuff was placed around the brachial artery and connected to the vascular testing system. The test provided measures of resting systolic and diastolic blood pressure, mean arterial pressure, pulse pressure, heart rate, and stroke volume.</p><p>After the pulse wave analysis test, the participants continued to rest in the supine position, and their shoulders were raised by 30 degrees for the aortic pulse wave velocity test. A neck pad was placed around the neck with a pressure pad over the right carotid area, secured with a Velcro fixing that was not too tight. A pressure cuff was placed around the right thigh and connected to the vascular testing system. The test provided a measure of pulse wave velocity indicative of arterial stiffness.</p></sec><sec id="sec2dot3dot2-jfmk-10-00148"><title>2.3.2. Venous Blood Measure</title><p>Circulating diabetic and inflammatory markers were evaluated, including hemoglobin A1c (HbA1c), fasting glucose, insulin (to estimate HOMA-IR using the equation fasting glucose*insulin/405), circulating C-reactive protein (CRP), and homocysteine. The participants were instructed to fast for 8 h before the assessment, with only water permitted during this time.</p><p>Blood samples were collected from subjects via venipuncture using serum-separating tubes (SST). Following collection, the tubes were allowed to clot for 30 min at room temperature and then centrifuged at 1500&#x000d7; <italic toggle="yes">g</italic> for 10 min to separate the serum. The resulting serum was carefully divided to avoid contamination from cellular material or the gel separator. Serum samples were stored at 4 &#x000b0;C until analysis and processed within 24 h to maintain sample integrity.</p><p>Each serum sample was pipetted directly into standardized cuvettes for the IR 1200 calorimetric analysis, ensuring consistent sample volumes across all measurements.</p><sec><title>HbA1c Analysis</title><p>The determination of hemoglobin A1c (HbA1c) levels was performed using the Diazyme Direct Enzymatic HbA1c Assay (Diazyme Laboratories, Poway, CA, USA). This method utilizes an enzymatic approach for the quantitative measurement of HbA1c in the whole blood samples, designed to provide reliable glycemic control monitoring. The Diazyme Direct Enzymatic HbA1c Assay was performed on an automated clinical chemistry analyzer. The HbA1c concentration was calculated using a calibration curve established with the provided calibrators. Quality control was maintained by testing two levels of HbA1c controls in each analytical run. The controls were provided in liquid or lyophilized form and stored at 2&#x02013;8 &#x000b0;C after preparation.</p></sec><sec><title>Glucose Analysis</title><p>Blood glucose concentrations were quantified using a Synermed Glucose IR070 reagent analyzer (Infrared Laboratory Systems, LLC, Westfield, IN, USA) on a spectrophotometer, employing an enzymatic glucose oxidase methodology for the determination of glucose levels in serum or plasma samples. The assay was performed according to the manufacturer&#x02019;s protocol. The absorbance reading, proportional to the glucose concentration, was compared to a calibration curve prepared using the Synermed glucose calibrator (300 mg/dL glucose). A protein-based reference material containing 300 mg/dL glucose was used for calibration, and calibration was performed daily prior to sample analysis. Quality control was ensured by testing normal and abnormal control materials, with acceptable ranges established by individual laboratories.</p></sec><sec><title>Insulin Analysis</title><p>The quantitative measurement of insulin in serum or heparinized plasma was performed using the IMMULITE 1000 Insulin Assay (Siemens Healthineers, Cary, NC, USA). Following the manufacturer&#x02019;s protocol, this method employed a solid-phase, enzyme-labeled chemiluminescent immunometric assay to detect and analyze insulin. The assay was calibrated using insulin adjustors, and calibration was performed as recommended by the manufacturer. Insulin controls were used to ensure assay accuracy and precision. Quality control samples were run in every assay batch, and results falling outside acceptable ranges triggered troubleshooting or recalibration.</p></sec><sec><title>CRP Analysis</title><p>The quantification of CRP was performed using a Diazyme High Sensitivity CRP (hsCRP) Assay kit (Diazyme Laboratories, Poway, CA, USA), which employs an enhanced immunoturbidimetric assay methodology for the in vitro determination of CRP concentrations in human serum and plasma samples. The assay was conducted on an automated clinical chemistry analyzer, following the manufacturer&#x02019;s instructions. The Diazyme hsCRP Calibrator set, consisting of four levels of CRP material, was utilized to establish the calibration curve. Calibration was performed every 14 days or as recommended by the manufacturer. Quality control was ensured using normal and abnormal CRP control materials, and control results were required to fall within acceptable ranges established by individual laboratories.</p></sec><sec><title>Homocysteine Analysis</title><p>The quantification of total L-homocysteine (Hcy) in serum and plasma was performed using a Diazyme Homocysteine 2 Reagent Enzymatic Assay kit (Diazyme Laboratories, Poway, CA, USA). The assay is based on an enzymatic conversion and co-substrate cycling system, allowing for the accurate determination of Hcy concentrations using an automated clinical chemistry analyzer equipped with absorbance measurement capabilities at 340 nm. The assay was calibrated using five levels of Hcy calibrator material. Calibration was performed at least every 5 days. Quality control was ensured by testing a set of normal and abnormal control materials. Laboratory-specific acceptable ranges were established for these controls.</p></sec></sec></sec><sec id="sec2dot4-jfmk-10-00148"><title>2.4. Statistical Analysis</title><p>Separate Pearson partial correlation analyses were used to determine the relationships between markers of systemic inflammation (CRP and homocysteine) and indicators of diabetes [HOMA-IR and Hemoglobin A1c (HbA1c)] while controlling for BF% and age (in years), which are related to systemic inflammation [<xref rid="B21-jfmk-10-00148" ref-type="bibr">21</xref>]. CRP and homocysteine were treated as predictor variables, and HOMA-IR and HbA1c were treated as outcome variables. SPSS version 29 was used for all analyses (&#x003b1; = 0.05). Data for each variable were screened for missing values and univariate outliers, defined as scores with a standardized value &#x02265; 3.0 standard deviation units from the group mean (Z &#x02265; 3.0). The results of the Shapiro&#x02013;Wilk test were interpreted to determine if each variable was normally distributed (<italic toggle="yes">p</italic> &#x0003e; 0.05). Violation of the assumption of normal distribution required a transformation procedure as appropriate so that planned parametric correlation analyses could proceed. The linear relationship between variables was verified using a visual interpretation of scatterplots with Loess lines. Data were screened for multivariate outliers defined as a Mahalanobis D value greater than the critical value of 18.47 (based on 4 variables per partial correlation analysis and an alpha level of 0.001). The correlation coefficient Pearson&#x02019;s <italic toggle="yes">r</italic> (<italic toggle="yes">r</italic>) ranged from &#x02212;1.0 to 1.0 and was interpreted according to direction (i.e., positive = direct relationship between variables; negative = indirect relationship between variables) and magnitude (0&#x02013;0.3 = weak relationship; 0.31&#x02013;0.5 = moderate relationship; 0.51&#x02013;1.0 = strong relationship).</p></sec></sec><sec sec-type="results" id="sec3-jfmk-10-00148"><title>3. Results</title><p>Cardiovascular and body composition characteristics are included in <xref rid="jfmk-10-00148-t001" ref-type="table">Table 1</xref>.</p><p>Univariate outliers (&#x02265;3.0 SD from the group mean) were detected for the variables CRP (1 outlier&#x02014;6.30; Z = 3.19), homocysteine (1 outlier&#x02014;26.79; Z = 3.02), and HOMA-IR (1 outlier&#x02014;6.97; Z = 3.09). These variables were removed from the respective correlation analyses via pairwise deletion. The analyses differ in terms of sample size for this reason. No multivariate outliers were detected. Descriptive statistics for each variable following the removal of outliers are presented in <xref rid="jfmk-10-00148-t002" ref-type="table">Table 2</xref>.</p><p>The variables HOMA-IR, HbA1c, and CRP violated the assumption of normality. All variables were transformed using the natural logarithm procedure [<xref rid="B22-jfmk-10-00148" ref-type="bibr">22</xref>], after which a normal distribution for the data for each variable was met. For variables with data values between 0 and 1, a constant was added to all scores so that the smallest value was 1.0 before logarithmic transformation [<xref rid="B23-jfmk-10-00148" ref-type="bibr">23</xref>].</p><p>The data were analyzed before and after transformation to better interpret the effect of data transformation on the relationships between variables of interest. For each version of the data (non-transformed and transformed), <italic toggle="yes">r</italic>-values and <italic toggle="yes">p</italic>-values are presented for zero-order correlations between variables (i.e., without controlling for BF% and age) and partial correlations between variables (<italic toggle="yes">r<sub>partial</sub></italic> and <italic toggle="yes">p<sub>partial</sub></italic>; i.e., controlling for BF% and age). All statistical results are presented in <xref rid="jfmk-10-00148-t003" ref-type="table">Table 3</xref> and summarized briefly in the text. Among the non-transformed (raw) scores, there was a strong, positive, and significant relationship between homocysteine and HbA1c. This relationship was still present after controlling for age and body fat percentage. The unstandardized beta correlation coefficient in this case was 0.10, which indicates that each 10 &#x003bc;mol/L increase in homocysteine is associated with a 1% increase in HbA1c. Transforming the scores to satisfy the assumption of a normal distribution did not substantially change the characteristics of the relationship between homocysteine and HbA1c. Finally, this relationship was still present after statistically controlling for age and body fat percentage in the analysis of the transformed scores. All of the remaining relationships investigated were not significant and ranged in magnitude from small to moderate.</p><p>Given that the results of the partial correlation analyses were not substantially or significantly different between the non-transformed and transformed versions of the scores, the visual depiction of the non-transformed scores are presented to increase the interpretability of the relationships between variables. These scatterplots are presented in <xref rid="jfmk-10-00148-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec sec-type="discussion" id="sec4-jfmk-10-00148"><title>4. Discussion</title><p>The findings of this study indicate a significant direct relationship between homocysteine and HbA1c levels among firefighters, even after adjusting for age and body fat percentage. This suggests that elevated homocysteine levels may contribute to poor glycemic control in this occupational group, thereby increasing their risk for diabetes and cardiovascular disease (CVD). For example, our results suggest that a 10 &#x003bc;mol/L increase in homocysteine is associated with a 1% increase in HbA1c, a hypothetical difference which would classify half of the 20 participants as having diabetes (HbA1c &#x02265; 6.5%) or pre-diabetes (5.7% &#x0003c; HbA1c &#x0003c; 6.5%) [<xref rid="B1-jfmk-10-00148" ref-type="bibr">1</xref>]. Given firefighting&#x02019;s strenuous and hazardous nature, understanding these metabolic relationships is crucial for developing targeted interventions.</p><p>Several studies support our findings of a direct correlation between homocysteine and HbA1c. Noor et al. conducted a study on 188 patients with type 2 diabetes and demonstrated that over 80% of the individuals had poor glycemic control (HbA1c &#x0003e; 7%). They found a positive correlation between HbA1c and serum homocysteine levels, with severe hyperhomocysteinemia in over 80% of the patients with an HbA1c greater than 7% [<xref rid="B24-jfmk-10-00148" ref-type="bibr">24</xref>]. Similarly, Kotchapetch et al. demonstrated a significant relationship between HbA1C and CRP in adults with pre-diabetes or diabetes [<xref rid="B25-jfmk-10-00148" ref-type="bibr">25</xref>]. They also found relationships between CRP, homocysteine, and BMI. While many studies confirm this association, others have failed to establish a significant link between hyperhomocysteinemia and glycemic control, suggesting that additional factors, such as inflammation and oxidative stress, may also play a role [<xref rid="B24-jfmk-10-00148" ref-type="bibr">24</xref>,<xref rid="B25-jfmk-10-00148" ref-type="bibr">25</xref>,<xref rid="B26-jfmk-10-00148" ref-type="bibr">26</xref>]. For instance, Zulfania et al. found no relationship between homocysteine and HbA1c or BMI in 125 patients with type 2 diabetes. However, homocysteine in this patient population was found to be related to systolic blood pressure [<xref rid="B27-jfmk-10-00148" ref-type="bibr">27</xref>].</p><p>Beyond its relationship with HbA1c, homocysteine has been linked to hypertension. Our study population demonstrated high systolic blood pressure (132.2 mmHg) and pulse pressure (62.3 mmHg) on average, conditions that have been associated with elevated homocysteine levels in other studies and contribute to greater cardiovascular risk [<xref rid="B28-jfmk-10-00148" ref-type="bibr">28</xref>,<xref rid="B29-jfmk-10-00148" ref-type="bibr">29</xref>]. However, the Framingham Heart Study, which included 2104 individuals without hypertension at baseline, failed to establish a causal relationship between homocysteine and hypertension, underscoring the complexity of these interactions [<xref rid="B30-jfmk-10-00148" ref-type="bibr">30</xref>].</p><p>To determine if body composition impacted the relationship between glycemic control and inflammatory markers, we demonstrated the results for controlling and not controlling for body fat percentage. Since our population may possess more muscle than the average population due to the physical nature of their occupation, we chose to analyze body fat percentage instead of BMI. Our results revealed that controlling for body fat percentage did not alter the overall declaration of significance between the variables. However, we did not assess the direct relationship between the firefighters&#x02019; body fat percentage and glycemic control or inflammatory markers. Pettersson-Pablo et al. showed a relationship between body fat percentage and inflammatory markers, including CRP, in healthy young adults [<xref rid="B31-jfmk-10-00148" ref-type="bibr">31</xref>]. Garcia-Rubira et al. explained the mechanisms linking obesity to the activation of inflammation primarily through the NLRP3 inflammasome. Since body fat may induce a proinflammatory state, controlling for body fat or BMI is imperative when assessing other markers related to inflammation [<xref rid="B32-jfmk-10-00148" ref-type="bibr">32</xref>].</p><p>Firefighters may be particularly susceptible to elevated homocysteine levels due to the inflammatory nature of their occupation. Exposure to fire emissions, including hazardous pollutants, can lead to acute and chronic systemic inflammation, which may elevate inflammatory markers, such as homocysteine levels [<xref rid="B5-jfmk-10-00148" ref-type="bibr">5</xref>]. Long-term firefighting careers have been associated with prolonged systemic inflammation, increasing the risk of cardiovascular and metabolic diseases [<xref rid="B33-jfmk-10-00148" ref-type="bibr">33</xref>,<xref rid="B34-jfmk-10-00148" ref-type="bibr">34</xref>]. Additionally, mild hyperhomocysteinemia is a known independent predictor of CVD, and firefighters&#x02019; increased vascular risk may be partially attributed to this metabolic disturbance [<xref rid="B35-jfmk-10-00148" ref-type="bibr">35</xref>,<xref rid="B36-jfmk-10-00148" ref-type="bibr">36</xref>].</p><p>To reduce inflammation and ultimately lower the risk of diabetes and cardiovascular disease (CVD) in firefighters, several practical interventions can be implemented. Strategies such as increasing dietary folate intake through supplementation or fortified foods have been shown to lower homocysteine concentrations effectively [<xref rid="B37-jfmk-10-00148" ref-type="bibr">37</xref>,<xref rid="B38-jfmk-10-00148" ref-type="bibr">38</xref>,<xref rid="B39-jfmk-10-00148" ref-type="bibr">39</xref>,<xref rid="B40-jfmk-10-00148" ref-type="bibr">40</xref>]. Furthermore, structured self-monitoring blood glucose interventions focusing on lowering HbA1c levels and improving glycemic control may also reduce systemic inflammation, as evidenced by reductions in high-sensitivity C-reactive protein (hs-CRP) levels [<xref rid="B41-jfmk-10-00148" ref-type="bibr">41</xref>]. Additionally, lifestyle modifications, including regular physical activity, a balanced diet, and stress management, can help mitigate inflammation and reduce the risk of chronic diseases in firefighters [<xref rid="B42-jfmk-10-00148" ref-type="bibr">42</xref>,<xref rid="B43-jfmk-10-00148" ref-type="bibr">43</xref>].</p><p>One limitation of this study includes the relatively small sample size of 20 participants. Correlation analyses with a sample size below 30 are highly sensitive to the influence of outliers, which could lead to conclusions that are not generalizable to the greater population [<xref rid="B44-jfmk-10-00148" ref-type="bibr">44</xref>]. Although we screened the data for outliers and transformed the data to yield a normally distributed set of scores, a larger sample would be more desirable to draw stronger conclusions about the relationships between inflammation and insulin resistance in this population. A second limitation of this study is the somewhat restricted range of the variables encountered in this generally healthy sample. For example, HbA1c did not exceed 6.1%, suggesting that this sample exhibited healthy glycemic control. The generalizability of the findings presented here may not extend to firefighters with impaired glycemic control.</p></sec><sec sec-type="conclusions" id="sec5-jfmk-10-00148"><title>5. Conclusions</title><p>This study revealed a significant relationship between HbA1c and homocysteine, even after controlling for body fat percentage and age. In other words, a higher level of homocysteine was associated with poorer glycemic control regardless of age or body composition. No relationship was found between HOMA-IR and either inflammatory marker or HbA1c and CRP. Follow-up studies should address this issue by collecting data from larger samples of firefighters with more heterogeneous health and metabolic function levels. Additionally, future research should incorporate lifestyle questionnaires to gain insights into health behaviors contributing to inflammation and interventions specifically designed to reduce inflammation and its metabolic consequences in firefighters. Addressing these factors may ultimately lead to reduced diabetes and CVD risk in this high-risk occupational group.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, T.J.O. and A.M.H.-W.; methodology, A.M.H.-W.; formal analysis, A.R.M.; investigation, A.A.K. and A.M.H.-W.; resources, A.M.H.-W.; writing&#x02014;original draft preparation, T.J.O., A.R.M. and A.M.H.-W.; writing&#x02014;review and editing, T.J.O., A.R.M., A.A.K. and A.M.H.-W.; supervision, A.M.H.-W. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Augusta University (IRBnet# 2095651 approved on 29 September 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data collected and analyzed for this study are freely available at the online data repository Open Science Framework via the following web address: <uri xlink:href="https://osf.io/js8ne/">https://osf.io/js8ne/</uri> (last updated 27 February 2025).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-jfmk-10-00148"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>E.</given-names></name>
<name><surname>Lim</surname><given-names>S.</given-names></name>
<name><surname>Lamptey</surname><given-names>R.</given-names></name>
<name><surname>Webb</surname><given-names>D.R.</given-names></name>
<name><surname>Davies</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Type 2 diabetes</article-title><source>Lancet</source><year>2022</year><volume>400</volume><fpage>1803</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)01655-5</pub-id><pub-id pub-id-type="pmid">36332637</pub-id>
</element-citation></ref><ref id="B2-jfmk-10-00148"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>M.K.</given-names></name>
<name><surname>Gouda</surname><given-names>G.</given-names></name>
<name><surname>Vadde</surname><given-names>R.</given-names></name>
</person-group><article-title>Relation Between Obesity and Type 2 Diabetes: Evolutionary Insights, Perspectives and Controversies</article-title><source>Curr. Obes. Rep.</source><year>2024</year><volume>13</volume><fpage>475</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1007/s13679-024-00572-1</pub-id><pub-id pub-id-type="pmid">38850502</pub-id>
</element-citation></ref><ref id="B3-jfmk-10-00148"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klein</surname><given-names>S.</given-names></name>
<name><surname>Gastaldelli</surname><given-names>A.</given-names></name>
<name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H.</given-names></name>
<name><surname>Scherer</surname><given-names>P.E.</given-names></name>
</person-group><article-title>Why does obesity cause diabetes?</article-title><source>Cell Metab.</source><year>2022</year><volume>34</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.12.012</pub-id><pub-id pub-id-type="pmid">34986330</pub-id>
</element-citation></ref><ref id="B4-jfmk-10-00148"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beckett</surname><given-names>A.</given-names></name>
<name><surname>Scott</surname><given-names>J.R.</given-names></name>
<name><surname>Chater</surname><given-names>A.M.</given-names></name>
<name><surname>Ferrandino</surname><given-names>L.</given-names></name>
<name><surname>Aldous</surname><given-names>J.W.F.</given-names></name>
</person-group><article-title>The Prevalence of Metabolic Syndrome and Its Components in Firefighters: A Systematic Review and Meta-Analysis</article-title><source>Int. J. Environ. Res. Public Health</source><year>2023</year><volume>20</volume><elocation-id>6814</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph20196814</pub-id><pub-id pub-id-type="pmid">37835084</pub-id>
</element-citation></ref><ref id="B5-jfmk-10-00148"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barros</surname><given-names>B.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.</given-names></name>
<name><surname>Morais</surname><given-names>S.</given-names></name>
</person-group><article-title>Firefighters&#x02019; occupational exposure: Contribution from biomarkers of effect to assess health risks</article-title><source>Environ. Int.</source><year>2021</year><volume>156</volume><fpage>106704</fpage><pub-id pub-id-type="doi">10.1016/j.envint.2021.106704</pub-id><pub-id pub-id-type="pmid">34161906</pub-id>
</element-citation></ref><ref id="B6-jfmk-10-00148"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Superko</surname><given-names>H.R.</given-names></name>
<name><surname>Momary</surname><given-names>K.M.</given-names></name>
<name><surname>Pendyala</surname><given-names>L.K.</given-names></name>
<name><surname>Williams</surname><given-names>P.T.</given-names></name>
<name><surname>Frohwein</surname><given-names>S.</given-names></name>
<name><surname>Garrett</surname><given-names>B.C.</given-names></name>
<name><surname>Skrifvars</surname><given-names>C.</given-names></name>
<name><surname>Gadesam</surname><given-names>R.</given-names></name>
<name><surname>King</surname><given-names>S.B.</given-names><suffix>3rd</suffix></name>
<name><surname>Rolader</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Firefighters, heart disease, and aspects of insulin resistance: The FEMA Firefighter Heart Disease Prevention study</article-title><source>J. Occup. Environ. Med.</source><year>2011</year><volume>53</volume><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1097/JOM.0b013e31821f64c3</pub-id><pub-id pub-id-type="pmid">21701401</pub-id>
</element-citation></ref><ref id="B7-jfmk-10-00148"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.F.</given-names></name>
<name><surname>Cui</surname><given-names>C.L.</given-names></name>
<name><surname>Wu</surname><given-names>P.</given-names></name>
<name><surname>Xie</surname><given-names>N.Z.</given-names></name>
</person-group><article-title>Relationship of serum homocysteine level with nutritional status and HbA1c level in elderly inpatients</article-title><source>Int. J. Clin. Exp. Med.</source><year>2013</year><volume>6</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">24179571</pub-id>
</element-citation></ref><ref id="B8-jfmk-10-00148"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Muntner</surname><given-names>P.</given-names></name>
<name><surname>Hamm</surname><given-names>L.L.</given-names></name>
<name><surname>Fonseca</surname><given-names>V.</given-names></name>
<name><surname>Batuman</surname><given-names>V.</given-names></name>
<name><surname>Whelton</surname><given-names>P.K.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
</person-group><article-title>Insulin resistance and risk of chronic kidney disease in nondiabetic US adults</article-title><source>J. Am. Soc. Nephrol.</source><year>2003</year><volume>14</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000046029.53933.09</pub-id><pub-id pub-id-type="pmid">12538749</pub-id>
</element-citation></ref><ref id="B9-jfmk-10-00148"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mossmann</surname><given-names>M.</given-names></name>
<name><surname>Wainstein</surname><given-names>M.V.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>S.C.</given-names></name>
<name><surname>Wainstein</surname><given-names>R.V.</given-names></name>
<name><surname>Gravina</surname><given-names>G.L.</given-names></name>
<name><surname>Sangalli</surname><given-names>M.</given-names></name>
<name><surname>Veadrigo</surname><given-names>F.</given-names></name>
<name><surname>Matte</surname><given-names>R.</given-names></name>
<name><surname>Reich</surname><given-names>R.</given-names></name>
<name><surname>Costa</surname><given-names>F.G.</given-names></name>
<etal/>
</person-group><article-title>HOMA-IR is associated with significant angiographic coronary artery disease in non-diabetic, non-obese individuals: A cross-sectional study</article-title><source>Diabetol. Metab. Syndr.</source><year>2015</year><volume>7</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1186/s13098-015-0085-5</pub-id><pub-id pub-id-type="pmid">26753001</pub-id>
</element-citation></ref><ref id="B10-jfmk-10-00148"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>A.</given-names></name>
<name><surname>Terrazzini</surname><given-names>N.</given-names></name>
<name><surname>Gage</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>B.J.</given-names></name>
<name><surname>Bradley</surname><given-names>R.</given-names></name>
<name><surname>Watt</surname><given-names>P.</given-names></name>
<name><surname>Watkins</surname><given-names>E.R.</given-names></name>
</person-group><article-title>Inflammatory and psychological consequences of chronic high exposure firefighting</article-title><source>J. Therm. Biol.</source><year>2023</year><volume>111</volume><elocation-id>103399</elocation-id><pub-id pub-id-type="doi">10.1016/j.jtherbio.2022.103399</pub-id><pub-id pub-id-type="pmid">36585074</pub-id>
</element-citation></ref><ref id="B11-jfmk-10-00148"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ridker</surname><given-names>P.M.</given-names></name>
<name><surname>Rifai</surname><given-names>N.</given-names></name>
<name><surname>Stampfer</surname><given-names>M.J.</given-names></name>
<name><surname>Hennekens</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.15.1767</pub-id><pub-id pub-id-type="pmid">10769275</pub-id>
</element-citation></ref><ref id="B12-jfmk-10-00148"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ridker</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Clinical application of C-reactive protein for cardiovascular disease detection and prevention</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000053730.47739.3C</pub-id><pub-id pub-id-type="pmid">12551853</pub-id>
</element-citation></ref><ref id="B13-jfmk-10-00148"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daniele</surname><given-names>G.</given-names></name>
<name><surname>Guardado Mendoza</surname><given-names>R.</given-names></name>
<name><surname>Winnier</surname><given-names>D.</given-names></name>
<name><surname>Fiorentino</surname><given-names>T.V.</given-names></name>
<name><surname>Pengou</surname><given-names>Z.</given-names></name>
<name><surname>Cornell</surname><given-names>J.</given-names></name>
<name><surname>Andreozzi</surname><given-names>F.</given-names></name>
<name><surname>Jenkinson</surname><given-names>C.</given-names></name>
<name><surname>Cersosimo</surname><given-names>E.</given-names></name>
<name><surname>Federici</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The inflammatory status score including IL-6, TNF-&#x003b1;, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus</article-title><source>Acta Diabetol.</source><year>2014</year><volume>51</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1007/s00592-013-0543-1</pub-id><pub-id pub-id-type="pmid">24370923</pub-id>
</element-citation></ref><ref id="B14-jfmk-10-00148"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Palfrey</surname><given-names>H.A.</given-names></name>
<name><surname>Pathak</surname><given-names>R.</given-names></name>
<name><surname>Kadowitz</surname><given-names>P.J.</given-names></name>
<name><surname>Gettys</surname><given-names>T.W.</given-names></name>
<name><surname>Murthy</surname><given-names>S.N.</given-names></name>
</person-group><article-title>The metabolism and significance of homocysteine in nutrition and health</article-title><source>Nutr. Metab.</source><year>2017</year><volume>14</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/s12986-017-0233-z</pub-id><pub-id pub-id-type="pmid">29299040</pub-id>
</element-citation></ref><ref id="B15-jfmk-10-00148"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sproston</surname><given-names>N.R.</given-names></name>
<name><surname>Ashworth</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Role of C-Reactive Protein at Sites of Inflammation and Infection</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>754</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00754</pub-id><pub-id pub-id-type="pmid">29706967</pub-id>
</element-citation></ref><ref id="B16-jfmk-10-00148"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saito</surname><given-names>I.</given-names></name>
<name><surname>Folsom</surname><given-names>A.R.</given-names></name>
<name><surname>Brancati</surname><given-names>F.L.</given-names></name>
<name><surname>Duncan</surname><given-names>B.B.</given-names></name>
<name><surname>Chambless</surname><given-names>L.E.</given-names></name>
<name><surname>McGovern</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study</article-title><source>Ann. Intern. Med.</source><year>2000</year><volume>133</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-133-2-200007180-00007</pub-id><pub-id pub-id-type="pmid">10896647</pub-id>
</element-citation></ref><ref id="B17-jfmk-10-00148"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Best</surname><given-names>L.G.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>E.T.</given-names></name>
<name><surname>Yeh</surname><given-names>J.L.</given-names></name>
<name><surname>Cowan</surname><given-names>L.</given-names></name>
<name><surname>Palmieri</surname><given-names>V.</given-names></name>
<name><surname>Roman</surname><given-names>M.</given-names></name>
<name><surname>Devereux</surname><given-names>R.B.</given-names></name>
<name><surname>Fabsitz</surname><given-names>R.R.</given-names></name>
<name><surname>Tracy</surname><given-names>R.P.</given-names></name>
<etal/>
</person-group><article-title>C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: The Strong Heart Study</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>1289</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.489260</pub-id><pub-id pub-id-type="pmid">16116058</pub-id>
</element-citation></ref><ref id="B18-jfmk-10-00148"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soinio</surname><given-names>M.</given-names></name>
<name><surname>Marniemi</surname><given-names>J.</given-names></name>
<name><surname>Laakso</surname><given-names>M.</given-names></name>
<name><surname>Lehto</surname><given-names>S.</given-names></name>
<name><surname>R&#x000f6;nnemaa</surname><given-names>T.</given-names></name>
</person-group><article-title>High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: A 7-year follow-up study</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.2337/diacare.29.02.06.dc05-1700</pub-id><pub-id pub-id-type="pmid">16443882</pub-id>
</element-citation></ref><ref id="B19-jfmk-10-00148"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>F&#x000e8;ve</surname><given-names>B.</given-names></name>
<name><surname>Bastard</surname><given-names>J.P.</given-names></name>
</person-group><article-title>The role of interleukins in insulin resistance and type 2 diabetes mellitus</article-title><source>Nat. Rev. Endocrinol.</source><year>2009</year><volume>5</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2009.62</pub-id><pub-id pub-id-type="pmid">19399017</pub-id>
</element-citation></ref><ref id="B20-jfmk-10-00148"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spranger</surname><given-names>J.</given-names></name>
<name><surname>Kroke</surname><given-names>A.</given-names></name>
<name><surname>M&#x000f6;hlig</surname><given-names>M.</given-names></name>
<name><surname>Hoffmann</surname><given-names>K.</given-names></name>
<name><surname>Bergmann</surname><given-names>M.M.</given-names></name>
<name><surname>Ristow</surname><given-names>M.</given-names></name>
<name><surname>Boeing</surname><given-names>H.</given-names></name>
<name><surname>Pfeiffer</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>812</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.2337/diabetes.52.3.812</pub-id><pub-id pub-id-type="pmid">12606524</pub-id>
</element-citation></ref><ref id="B21-jfmk-10-00148"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frasca</surname><given-names>D.</given-names></name>
<name><surname>Blomberg</surname><given-names>B.B.</given-names></name>
<name><surname>Paganelli</surname><given-names>R.</given-names></name>
</person-group><article-title>Aging, Obesity, and Inflammatory Age-Related Diseases</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><elocation-id>1745</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01745</pub-id><pub-id pub-id-type="pmid">29270179</pub-id>
</element-citation></ref><ref id="B22-jfmk-10-00148"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>West</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Best practice in statistics: The use of log transformation</article-title><source>Ann. Clin. Biochem.</source><year>2022</year><volume>59</volume><fpage>162</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1177/00045632211050531</pub-id><pub-id pub-id-type="pmid">34666549</pub-id>
</element-citation></ref><ref id="B23-jfmk-10-00148"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osborne</surname><given-names>J.</given-names></name>
</person-group><article-title>Notes on the use of data transformations</article-title><source>Pract. Assess. Res. Eval.</source><year>2002</year><volume>8</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.7275/4vng-5608</pub-id></element-citation></ref><ref id="B24-jfmk-10-00148"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noor</surname><given-names>A.</given-names></name>
<name><surname>Rahman</surname><given-names>M.U.</given-names></name>
<name><surname>Faraz</surname><given-names>N.</given-names></name>
<name><surname>Samin</surname><given-names>K.A.</given-names></name>
<name><surname>Ullah</surname><given-names>H.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group><article-title>Relationship of Homocysteine with Gender, Blood Pressure, Body Mass Index, Hemoglobin A1c, and the Duration of Diabetes Mellitus Type 2</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e19211</fpage><pub-id pub-id-type="doi">10.7759/cureus.19211</pub-id><pub-id pub-id-type="pmid">34877198</pub-id>
</element-citation></ref><ref id="B25-jfmk-10-00148"><label>25.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Kotchapetch</surname><given-names>H.</given-names></name>
<name><surname>Rintra</surname><given-names>J.</given-names></name>
<name><surname>Sittiprapaporn</surname><given-names>P.</given-names></name>
</person-group><article-title>Association Between HBA1C and Inflammatory Markers: HS-CRP and Homocysteine</article-title><source>Proceedings of the AU Hybrid International Conference 2024 on &#x0201c;Entrepreneurship &#x00026; Sustainability in the Digital Era&#x0201d; Under the Theme of &#x0201c;People Centric Knowledge in Intelligence World&#x0201d;</source><conf-loc>Hua Mak, Thailand</conf-loc><conf-date>26 April 2024</conf-date><fpage>458</fpage><lpage>464</lpage></element-citation></ref><ref id="B26-jfmk-10-00148"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoogeveen</surname><given-names>E.K.</given-names></name>
<name><surname>Kostense</surname><given-names>P.J.</given-names></name>
<name><surname>Jakobs</surname><given-names>C.</given-names></name>
<name><surname>Dekker</surname><given-names>J.M.</given-names></name>
<name><surname>Nijpels</surname><given-names>G.</given-names></name>
<name><surname>Heine</surname><given-names>R.J.</given-names></name>
<name><surname>Bouter</surname><given-names>L.M.</given-names></name>
<name><surname>Stehouwer</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>1506</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.13.1506</pub-id><pub-id pub-id-type="pmid">10747342</pub-id>
</element-citation></ref><ref id="B27-jfmk-10-00148"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zulfania Khan</surname><given-names>A.</given-names></name>
<name><surname>Rehman</surname><given-names>S.</given-names></name>
<name><surname>Ghaffar</surname><given-names>T.</given-names></name>
</person-group><article-title>Association of homocysteine with body mass index, blood pressure, HbA1c and duration of diabetes in type 2 diabetics</article-title><source>Pak. J. Med. Sci.</source><year>2018</year><volume>34</volume><fpage>1483</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.12669/pjms.346.16032</pub-id><pub-id pub-id-type="pmid">30559808</pub-id>
</element-citation></ref><ref id="B28-jfmk-10-00148"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Passaro</surname><given-names>A.</given-names></name>
<name><surname>Calzoni</surname><given-names>F.</given-names></name>
<name><surname>Volpato</surname><given-names>S.</given-names></name>
<name><surname>Nora</surname><given-names>E.D.</given-names></name>
<name><surname>Pareschi</surname><given-names>P.L.</given-names></name>
<name><surname>Zamboni</surname><given-names>P.F.</given-names></name>
<name><surname>Fellin</surname><given-names>R.</given-names></name>
<name><surname>Solini</surname><given-names>A.</given-names></name>
</person-group><article-title>Effect of metabolic control on homocysteine levels in type 2 diabetic patients: A 3-year follow-up</article-title><source>J. Intern. Med.</source><year>2003</year><volume>254</volume><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2796.2003.01184.x</pub-id><pub-id pub-id-type="pmid">12930236</pub-id>
</element-citation></ref><ref id="B29-jfmk-10-00148"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>J.C.</given-names></name>
<name><surname>Kuo</surname><given-names>H.T.</given-names></name>
<name><surname>Chiu</surname><given-names>Y.W.</given-names></name>
<name><surname>Hwang</surname><given-names>S.J.</given-names></name>
<name><surname>Chuang</surname><given-names>H.Y.</given-names></name>
<name><surname>Chang</surname><given-names>J.M.</given-names></name>
<name><surname>Chen</surname><given-names>H.C.</given-names></name>
<name><surname>Lai</surname><given-names>Y.H.</given-names></name>
</person-group><article-title>Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients</article-title><source>Atherosclerosis</source><year>2005</year><volume>182</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2005.01.038</pub-id><pub-id pub-id-type="pmid">16115482</pub-id>
</element-citation></ref><ref id="B30-jfmk-10-00148"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sundstr&#x000f6;m</surname><given-names>J.</given-names></name>
<name><surname>Sullivan</surname><given-names>L.</given-names></name>
<name><surname>D&#x02019;Agostino</surname><given-names>R.B.</given-names></name>
<name><surname>Jacques</surname><given-names>P.F.</given-names></name>
<name><surname>Selhub</surname><given-names>J.</given-names></name>
<name><surname>Rosenberg</surname><given-names>I.H.</given-names></name>
<name><surname>Wilson</surname><given-names>P.W.</given-names></name>
<name><surname>Levy</surname><given-names>D.</given-names></name>
<name><surname>Vasan</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Plasma homocysteine, hypertension incidence, and blood pressure tracking: The Framingham Heart Study</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>1100</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000101690.58391.13</pub-id><pub-id pub-id-type="pmid">14597642</pub-id>
</element-citation></ref><ref id="B31-jfmk-10-00148"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pettersson-Pablo</surname><given-names>P.</given-names></name>
<name><surname>Nilsson</surname><given-names>T.K.</given-names></name>
<name><surname>Breimer</surname><given-names>L.H.</given-names></name>
<name><surname>Hurtig-Wennl&#x000f6;f</surname><given-names>A.</given-names></name>
</person-group><article-title>Body fat percentage is more strongly associated with biomarkers of low-grade inflammation than traditional cardiometabolic risk factors in healthy young adults&#x02014;The Lifestyle, Biomarkers, and Atherosclerosis study</article-title><source>Scand. J. Clin. Lab. Investig.</source><year>2019</year><volume>79</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1080/00365513.2019.1576219</pub-id><pub-id pub-id-type="pmid">30767573</pub-id>
</element-citation></ref><ref id="B32-jfmk-10-00148"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia-Rubira</surname><given-names>J.C.</given-names></name>
<name><surname>Cano-Garcia</surname><given-names>F.J.</given-names></name>
<name><surname>Bullon</surname><given-names>B.</given-names></name>
<name><surname>Seoane</surname><given-names>T.</given-names></name>
<name><surname>Villar</surname><given-names>P.V.</given-names></name>
<name><surname>Cordero</surname><given-names>M.D.</given-names></name>
<name><surname>Bullon</surname><given-names>P.</given-names></name>
</person-group><article-title>Body fat and metabolic age as indicators of inflammation and cardiovascular risk</article-title><source>Eur. J. Prev. Cardiol.</source><year>2018</year><volume>25</volume><fpage>233</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1177/2047487317744051</pub-id><pub-id pub-id-type="pmid">29164910</pub-id>
</element-citation></ref><ref id="B33-jfmk-10-00148"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liberale</surname><given-names>L.</given-names></name>
<name><surname>Montecucco</surname><given-names>F.</given-names></name>
<name><surname>Tardif</surname><given-names>J.C.</given-names></name>
<name><surname>Libby</surname><given-names>P.</given-names></name>
<name><surname>Camici</surname><given-names>G.G.</given-names></name>
</person-group><article-title>Inflamm-ageing: The role of inflammation in age-dependent cardiovascular disease</article-title><source>Eur. Heart J.</source><year>2020</year><volume>41</volume><fpage>2974</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehz961</pub-id><pub-id pub-id-type="pmid">32006431</pub-id>
</element-citation></ref><ref id="B34-jfmk-10-00148"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navarro</surname><given-names>K.M.</given-names></name>
<name><surname>Kleinman</surname><given-names>M.T.</given-names></name>
<name><surname>Mackay</surname><given-names>C.E.</given-names></name>
<name><surname>Reinhardt</surname><given-names>T.E.</given-names></name>
<name><surname>Balmes</surname><given-names>J.R.</given-names></name>
<name><surname>Broyles</surname><given-names>G.A.</given-names></name>
<name><surname>Ottmar</surname><given-names>R.D.</given-names></name>
<name><surname>Naher</surname><given-names>L.P.</given-names></name>
<name><surname>Domitrovich</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Wildland firefighter smoke exposure and risk of lung cancer and cardiovascular disease mortality</article-title><source>Environ. Res.</source><year>2019</year><volume>173</volume><fpage>462</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.envres.2019.03.060</pub-id><pub-id pub-id-type="pmid">30981117</pub-id>
</element-citation></ref><ref id="B35-jfmk-10-00148"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brattstr&#x000f6;m</surname><given-names>L.</given-names></name>
<name><surname>Wilcken</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Homocysteine and cardiovascular disease: Cause or effect?</article-title><source>Am. J. Clin. Nutr.</source><year>2000</year><volume>72</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1093/ajcn/72.2.315</pub-id><pub-id pub-id-type="pmid">10919920</pub-id>
</element-citation></ref><ref id="B36-jfmk-10-00148"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smulders</surname><given-names>Y.M.</given-names></name>
<name><surname>Blom</surname><given-names>H.J.</given-names></name>
</person-group><article-title>The homocysteine controversy</article-title><source>J. Inherit. Metab. Dis.</source><year>2011</year><volume>34</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s10545-010-9151-1</pub-id><pub-id pub-id-type="pmid">20567905</pub-id>
</element-citation></ref><ref id="B37-jfmk-10-00148"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riddell</surname><given-names>L.J.</given-names></name>
<name><surname>Chisholm</surname><given-names>A.</given-names></name>
<name><surname>Williams</surname><given-names>S.</given-names></name>
<name><surname>Mann</surname><given-names>J.I.</given-names></name>
</person-group><article-title>Dietary strategies for lowering homocysteine concentrations</article-title><source>Am. J. Clin. Nutr.</source><year>2000</year><volume>71</volume><fpage>1448</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1093/ajcn/71.6.1448</pub-id><pub-id pub-id-type="pmid">10837284</pub-id>
</element-citation></ref><ref id="B38-jfmk-10-00148"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malinow</surname><given-names>M.R.</given-names></name>
<name><surname>Duell</surname><given-names>P.B.</given-names></name>
<name><surname>Hess</surname><given-names>D.L.</given-names></name>
<name><surname>Anderson</surname><given-names>P.H.</given-names></name>
<name><surname>Kruger</surname><given-names>W.D.</given-names></name>
<name><surname>Phillipson</surname><given-names>B.E.</given-names></name>
<name><surname>Gluckman</surname><given-names>R.A.</given-names></name>
<name><surname>Block</surname><given-names>P.C.</given-names></name>
<name><surname>Upson</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease</article-title><source>N. Engl. J. Med.</source><year>1998</year><volume>338</volume><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1056/NEJM199804093381501</pub-id><pub-id pub-id-type="pmid">9535664</pub-id>
</element-citation></ref><ref id="B39-jfmk-10-00148"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nyg&#x000e5;rd</surname><given-names>O.</given-names></name>
<name><surname>Refsum</surname><given-names>H.</given-names></name>
<name><surname>Ueland</surname><given-names>P.M.</given-names></name>
<name><surname>Vollset</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study</article-title><source>Am. J. Clin. Nutr.</source><year>1998</year><volume>67</volume><fpage>263</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1093/ajcn/67.2.263</pub-id><pub-id pub-id-type="pmid">9459374</pub-id>
</element-citation></ref><ref id="B40-jfmk-10-00148"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moat</surname><given-names>S.J.</given-names></name>
<name><surname>Lang</surname><given-names>D.</given-names></name>
<name><surname>McDowell</surname><given-names>I.F.</given-names></name>
<name><surname>Clarke</surname><given-names>Z.L.</given-names></name>
<name><surname>Madhavan</surname><given-names>A.K.</given-names></name>
<name><surname>Lewis</surname><given-names>M.J.</given-names></name>
<name><surname>Goodfellow</surname><given-names>J.</given-names></name>
</person-group><article-title>Folate, homocysteine, endothelial function and cardiovascular disease</article-title><source>J. Nutr. Biochem.</source><year>2004</year><volume>15</volume><fpage>64</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2003.08.010</pub-id><pub-id pub-id-type="pmid">14972346</pub-id>
</element-citation></ref><ref id="B41-jfmk-10-00148"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schnell</surname><given-names>O.</given-names></name>
<name><surname>Amann-Zalan</surname><given-names>I.</given-names></name>
<name><surname>Jelsovsky</surname><given-names>Z.</given-names></name>
<name><surname>Moritz</surname><given-names>A.</given-names></name>
<name><surname>Bermejo</surname><given-names>J.L.</given-names></name>
<name><surname>Parkin</surname><given-names>C.G.</given-names></name>
<name><surname>Schweitzer</surname><given-names>M.A.</given-names></name>
<name><surname>Fisher</surname><given-names>L.</given-names></name>
<name><surname>Polonsky</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Changes in A1C levels are significantly associated with changes in levels of the cardiovascular risk biomarker hs-CRP: Results from the SteP study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>2084</fpage><lpage>2089</lpage><pub-id pub-id-type="doi">10.2337/dc12-1711</pub-id><pub-id pub-id-type="pmid">23435160</pub-id>
</element-citation></ref><ref id="B42-jfmk-10-00148"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orysiak</surname><given-names>J.</given-names></name>
<name><surname>M&#x00142;ynarczyk</surname><given-names>M.</given-names></name>
<name><surname>Piec</surname><given-names>R.</given-names></name>
<name><surname>Jakubiak</surname><given-names>A.</given-names></name>
</person-group><article-title>Lifestyle and environmental factors may induce airway and systemic inflammation in firefighters</article-title><source>Environ. Sci. Pollut. Res. Int.</source><year>2022</year><volume>29</volume><fpage>73741</fpage><lpage>73768</lpage><pub-id pub-id-type="doi">10.1007/s11356-022-22479-x</pub-id><pub-id pub-id-type="pmid">36094704</pub-id>
</element-citation></ref><ref id="B43-jfmk-10-00148"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soteriades</surname><given-names>E.S.</given-names></name>
<name><surname>Smith</surname><given-names>D.L.</given-names></name>
<name><surname>Tsismenakis</surname><given-names>A.J.</given-names></name>
<name><surname>Baur</surname><given-names>D.M.</given-names></name>
<name><surname>Kales</surname><given-names>S.N.</given-names></name>
</person-group><article-title>Cardiovascular disease in US firefighters: A systematic review</article-title><source>Cardiol. Rev.</source><year>2011</year><volume>19</volume><fpage>202</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1097/CRD.0b013e318215c105</pub-id><pub-id pub-id-type="pmid">21646874</pub-id>
</element-citation></ref><ref id="B44-jfmk-10-00148"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Warner</surname><given-names>R.</given-names></name>
</person-group><source>Applied Statistics: From Bivariate Through Multivariate Techniques</source><edition>3rd ed.</edition><publisher-name>Sage Publications, Inc.</publisher-name><publisher-loc>Thousand Oaks, CA, USA</publisher-loc><year>2021</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jfmk-10-00148-f001"><label>Figure 1</label><caption><p>Scatterplots showing the visual representation of the relationships between the non-transformed version of variables: (<bold>a</bold>) C-reactive protein (CRP) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR); (<bold>b</bold>) CRP and glycated hemoglobin (HbA1c); (<bold>c</bold>) homocysteine and HOMA-IR; and (<bold>d</bold>) homocysteine and HbA1c. The blue dashed line is the trendline that corresponds to the data points of the individuals plotted as black dots.</p></caption><graphic xlink:href="jfmk-10-00148-g001" position="float"/></fig><table-wrap position="float" id="jfmk-10-00148-t001"><object-id pub-id-type="pii">jfmk-10-00148-t001_Table 1</object-id><label>Table 1</label><caption><p>Mean cardiovascular and body composition characteristics for the 20 male participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Resting Cardiovascular Characteristics</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measure (Unit)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean &#x000b1; Standard Deviation</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Systolic Blood Pressure (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">132.2 &#x000b1; 8.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diastolic Blood Pressure (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">70.6 &#x000b1; 9.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pulse Pressure (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">62.3 &#x000b1; 5.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mean Arterial Pressure (mmHg)</td><td align="center" valign="middle" rowspan="1" colspan="1">94.7 &#x000b1; 8.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Heart Rate (bpm)</td><td align="center" valign="middle" rowspan="1" colspan="1">57.4 &#x000b1; 7.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Estimate Stroke Volume (mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">115.7 &#x000b1; 21.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Peripheral Resistance (PRU)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 &#x000b1; 0.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulse Wave Velocity (m/s)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.5 &#x000b1; 0.9</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Body Composition Characteristics</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Weight (lb)</td><td align="center" valign="middle" rowspan="1" colspan="1">220.8 &#x000b1; 39.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Height (in)</td><td align="center" valign="middle" rowspan="1" colspan="1">70.8 &#x000b1; 2.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">31.0 &#x000b1; 5.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Body Fat (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">28.1 &#x000b1; 7.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lean Body Mass (lb)</td><td align="center" valign="middle" rowspan="1" colspan="1">156.7 &#x000b1; 19.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Body Water (lb)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115.1 &#x000b1; 14.0</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jfmk-10-00148-t002"><object-id pub-id-type="pii">jfmk-10-00148-t002_Table 2</object-id><label>Table 2</label><caption><p>Descriptive statistics for the variables used in the formal statistical analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable (Units)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Standard Deviation</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP (mg/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.342</td><td align="center" valign="middle" rowspan="1" colspan="1">0.998</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Homocysteine (&#x003bc;mol/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.698</td><td align="center" valign="middle" rowspan="1" colspan="1">1.083</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HOMA-IR</td><td align="center" valign="middle" rowspan="1" colspan="1">1.592</td><td align="center" valign="middle" rowspan="1" colspan="1">1.083</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.645</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.505</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jfmk-10-00148-t003"><object-id pub-id-type="pii">jfmk-10-00148-t003_Table 3</object-id><label>Table 3</label><caption><p>Statistical results for zero-order and partial correlation between variables, before and after transformation.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Variables</bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>Zero-Order Correlations</bold>
</td><td colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<bold>Partial Correlations</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">r</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">r<sub>partial</sub></italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p<sub>partial</sub></italic>
</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Non-transformed scores</td><td align="left" valign="middle" rowspan="1" colspan="1">CRP</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HOMA-IR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.170</td><td align="center" valign="middle" rowspan="1" colspan="1">0.499</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.024</td><td align="center" valign="middle" rowspan="1" colspan="1">0.929</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HbA1c</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.144</td><td align="center" valign="middle" rowspan="1" colspan="1">0.556</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.059</td><td align="center" valign="middle" rowspan="1" colspan="1">0.822</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Homocysteine</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HOMA-IR</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.069</td><td align="center" valign="middle" rowspan="1" colspan="1">0.787</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.351</td><td align="center" valign="middle" rowspan="1" colspan="1">0.183</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;HbA1c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.643</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.632</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Variables</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Zero-Order Correlations</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Partial Correlations</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">r</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">r<sub>partial</sub></italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p<sub>partial</sub></italic>
</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Transformed scores</td><td align="left" valign="middle" rowspan="1" colspan="1">CRP</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HOMA-IR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.231</td><td align="center" valign="middle" rowspan="1" colspan="1">0.356</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.063</td><td align="center" valign="middle" rowspan="1" colspan="1">0.818</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HbA1c</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.150</td><td align="center" valign="middle" rowspan="1" colspan="1">0.541</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.083</td><td align="center" valign="middle" rowspan="1" colspan="1">0.752</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Homocysteine</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;HOMA-IR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td><td align="center" valign="middle" rowspan="1" colspan="1">0.964</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.305</td><td align="center" valign="middle" rowspan="1" colspan="1">0.250</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;HbA1c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.605</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.588</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013 *</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: * = indicates a significant relationship. Zero-order correlations are the correlation analysis results without controlling for age and body fat percentage.</p></fn></table-wrap-foot></table-wrap></floats-group></article>